302 related articles for article (PubMed ID: 28807236)
1. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
Zeidan AM; Pullarkat VA; Komrokji RS
Crit Rev Oncol Hematol; 2017 Sep; 117():57-66. PubMed ID: 28807236
[TBL] [Abstract][Full Text] [Related]
2. To chelate or not to chelate in MDS: That is the question!
Zeidan AM; Griffiths EA
Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
[TBL] [Abstract][Full Text] [Related]
3. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Leitch HA; Vickars LM
Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
[TBL] [Abstract][Full Text] [Related]
4. Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Mitchell M; Gore SD; Zeidan AM
Expert Rev Hematol; 2013 Aug; 6(4):397-410. PubMed ID: 23991926
[TBL] [Abstract][Full Text] [Related]
5. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
6. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Gattermann N
Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
[TBL] [Abstract][Full Text] [Related]
7. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
Wong CAC; Wong SAY; Leitch HA
Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
[TBL] [Abstract][Full Text] [Related]
8. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
Leitch HA; Gattermann N
Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
[TBL] [Abstract][Full Text] [Related]
9. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
Imran F; Phatak P
Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
[TBL] [Abstract][Full Text] [Related]
10. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
[TBL] [Abstract][Full Text] [Related]
11. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
[TBL] [Abstract][Full Text] [Related]
12. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
Shammo JM; Komrokji RS
Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.
Ko BS; Chang CS; Chang MC; Chen TY; Chiou TJ; Chiu CF; Huang WL; Kao WY; Lan YJ; Lin SF; Tan TD; Tang JL; Tzeng CH; Wang PN; Yet SP; Tien HF
Int J Hematol; 2014 Jul; 100(1):7-15. PubMed ID: 24924953
[TBL] [Abstract][Full Text] [Related]
14. Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes.
Carreau N; Tremblay D; Savona M; Kremyanskaya M; Mascarenhas J
Blood Rev; 2016 Sep; 30(5):349-56. PubMed ID: 27106071
[TBL] [Abstract][Full Text] [Related]
15. Iron overload in patients with myelodysplastic syndromes.
Jensen PD
Curr Hematol Malig Rep; 2007 Feb; 2(1):13-21. PubMed ID: 20425384
[TBL] [Abstract][Full Text] [Related]
16. Iron overload in myelodysplastic syndromes: diagnosis and management.
List AF
Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
[TBL] [Abstract][Full Text] [Related]
17. Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis.
Liu H; Yang N; Meng S; Zhang Y; Zhang H; Zhang W
Clin Exp Med; 2020 Feb; 20(1):1-9. PubMed ID: 31712933
[TBL] [Abstract][Full Text] [Related]
18. Controversies surrounding iron chelation therapy for MDS.
Leitch HA
Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
[TBL] [Abstract][Full Text] [Related]
19. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
20. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch HA
Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]